This offering represents a distress capital raise from a company on the brink of delisting with no revenue stream. The dilution from raising up to $1.2 million on a $2 million market cap is extreme. Traders should anticipate continued downward pressure on the stock price, potential delisting to OTC markets, and possible bankruptcy if the company cannot secure additional funding. The offering confirms the company's survival is in serious jeopardy.
INM drugs
INM drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 6 $0.6950entry
- T+1 · 7mo ago −2.16%α −2.22% · $0.6800
- T+5 · 7mo ago +2.59%α −1.54% · $0.7130
- T+20 · 7mo ago +7.63%α −1.36% · $0.7480
- T+60 · 5mo ago +128.78%α +115.31% · $1.59
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
InMed Pharmaceuticals is conducting an at-the-market offering of up to $1.2 million in common shares through H.C. Wainwright & Co. This offering occurs amid severe financial distress, including a Nasdaq delisting notice due to low stock price and the wind down of its only revenue-generating business segment, BayMedica, due to adverse U.S. legislation. The company faces substantial doubt about its ability to continue as a going concern.
Key Facts
- Company is offering up to $1,213,648 in common shares through an at-the-market offering with H.C. Wainwright & Co.
- Stock received Nasdaq delisting notice on March 27, 2026 for failing to maintain $1.00 minimum bid price for 30 consecutive days.
- Company is winding down BayMedica, its only revenue-generating business segment, due to H.R. 5371 legislation that will prohibit aspects of its commercial business.
- Company has incurred significant operating losses: $3.8 million for six months ended December 31, 2025 and $8.2 million for the year ended June 30, 2025.
- Auditors have included going concern doubts in financial statements due to recurring losses and negative cash flows.
- Market cap is only $2 million with stock trading at $0.67 per share as of April 1, 2026.
Financial Impact
Up to $1.2 million in dilutive equity issuance from a $2 million market cap company, representing up to 60% of market value. The offering comes after a $50 million shelf registration, indicating potential for significant further dilution.
Risk Factors
- Substantial doubt about the company's ability to continue as a going concern
- Imminent delisting from Nasdaq if stock price doesn't recover to $1.00
- Complete loss of revenue stream from wind down of BayMedica operations
- Extreme shareholder dilution from capital raise on minimal market cap
- Potential bankruptcy if unable to secure additional financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001213900-26-039938 |
| Document: 0001213900-26-039938-index-headers.html | 0001213900-26-039938 |
| Document: 0001213900-26-039938-index.html | 0001213900-26-039938 |
| Document: 0001213900-26-039938.txt | 0001213900-26-039938 |
Track record
22 reports on INM
6 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +24.51% at T+1 after the Nov 3, 2026 report. 9 of 11 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 3, 202613d ago 8-K Bearish 6/10 Entry $1.75 Now $19.87 −1035.43% settles Dec 3
- Nov 2, 202614d ago 425 Neutral 3/10 Entry $1.68 Now $19.87 +1082.74% settles Dec 2
- Oct 26, 202621d ago 425 Neutral 3/10 Entry $1.59 Now $19.87 +1149.69% settles Nov 24
- Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $1.33 to $1.32 Now $19.87 +1393.99% ▼ −0.68% +4.61% vs SPY
- Oct 2, 20266w ago EFFECT Neutral 3/10 Entry $1.33 to $1.60 Now $19.87 +1393.99% ▲ +20.30% +22.11% vs SPY
- Sep 18, 20268w ago 8-K Bearish 6/10 Entry $1.38 to $1.37 Now $19.87 −1339.86% ▲ +1.06% +0.15% vs SPY
- Sep 9, 20269w ago 425 Neutral 6/10 Entry $1.31 to $1.33 Now $19.87 +1416.79% ▲ +1.53% −0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers